News
TRIKAFTA Triple Combo Therapy for Cystic Fibrosis
Date: 11/19/2019
Foundation Care has been selected as one of the limited dispensing pharmacies for TRIKAFTA, the highly anticipated, triple combo therapy for cystic fibrosis (CF). As a CF Center of Excellence, Foundation Care provides medication and support to CF patients, ensuring specialized care to meet the individual health needs of each individual.
TRIKAFTA
TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a breakthrough prescription medicine that has demonstrated significant improvements in lung function, with potential to treat the underlying cause of CF in a large majority of patients. TRIKAFTA is approved for patients 12 years and older with CF who have at least one F508del mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, estimated to affect 90 percent of the CF population.
Specialized Service and Support
In addition to dispensing TRIKAFTA, Foundation Care will provide prescribed patients the with high-touch, quality care and support needed to be successful on their new therapy. This support includes a specially trained team created to ensure quality care to patients on TRIKAFTA. The team will be a key resource for prior authorization support, assisting clinics to manage patient demand for this therapy.
“Foundation Care is pleased to build on our partnership with Vertex,” said Dan Blakeley, President of Foundation Care. “With the addition of TRIKAFTA to our list of products and services for our CF patients, we continue to be the only pharmacy that provides complete services for our CF patients, including all CF medications, compounded medications, retail pharmacy products and durable medical equipment. We are able to provide an innovative drug therapy to our CF patients. This, combined with our highly-trained support team will ensure seamless, specialized patient care.”
To learn more about Foundation Care’s approach to CF care and TRIKAFTA, please call 877.291.1122 or visit our TRIKAFTA page.